Panel: Targeted approaches to combinations, what’s working?

 · What strategies can we use to identify the best combinations?  

o Using immunology as a guide?  

o Combinations of any active compound? 

· What are the major mechanisms we need to focus on?  

· How successful have targeted combinations been so far?  

o IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents 

· What are the best biomarkers for combination studies? 

· What major challenges remain?